Achieve Life Sciences (ACHV) Net Cash Flow (2010 - 2026)
Achieve Life Sciences' (ACHV) quarterly Net Cash Flow came in at $7.4 million in Q1 2026, up 2679.25% YoY from $265000.0 in Q1 2025, and up 166.71% on a QoQ basis from -$11.0 million in Q4 2025.
Achieve Life Sciences (ACHV) Net Cash Flow (2010 - 2026) Analysis & Trends
Achieve Life Sciences (ACHV) has 17 years of Net Cash Flow data on file, last reported at $7.4 million in Q1 2026.
- Quarterly Net Cash Flow rose 2679.25% year-over-year to $7.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$26.0 million (down 281.44% YoY) and the FY2025 annual result came in at $8.1 million, up 388.27% from the prior year.
- Net Cash Flow improved to $7.4 million in Q1 2026, from -$11.0 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $50.8 million in Q1 2024 to a low of -$19.9 million in Q3 2025.
- A 5-year average of -$555000.0 and a median of -$5.1 million in 2024 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2025 — Net Cash Flow sank 443.93% — and 2026, when it soared 2679.25%.
- Tracing ACHV's Net Cash Flow over 5 years: stood at $6.6 million in 2022, then tumbled by 166.51% to -$4.4 million in 2023, then surged by 173.46% to $3.2 million in 2024, then slumped by 443.93% to -$11.0 million in 2025, then surged by 166.71% to $7.4 million in 2026.
- The last three Net Cash Flow figures came in at $7.4 million (Q1 2026), -$11.0 million (Q4 2025), and -$19.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Achieve Life Sciences | 330.88 Mn | 330.88 Mn | - | 19.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.88 Mn |
| Jun 30, 2026 | 19.88 Mn |
| Mar 31, 2026 | 7.37 Mn |
| Mar 31, 2026 | 7.37 Mn |
| Dec 31, 2025 | -11.04 Mn |
| Dec 31, 2025 | -11.04 Mn |
| Sep 30, 2025 | -19.90 Mn |
| Sep 30, 2025 | -19.90 Mn |
| Jun 30, 2025 | -2.41 Mn |
| Jun 30, 2025 | -2.41 Mn |
| Mar 31, 2025 | 265,000.00 |
| Mar 31, 2025 | 265,000.00 |
| Dec 31, 2024 | 3.21 Mn |
| Dec 31, 2024 | 3.21 Mn |
| Sep 30, 2024 | -5.21 Mn |
| Sep 30, 2024 | -5.21 Mn |
| Jun 30, 2024 | -5.07 Mn |
| Jun 30, 2024 | -5.07 Mn |
| Mar 31, 2024 | 50.82 Mn |
| Mar 31, 2024 | 50.82 Mn |